Evidence map›Paper›PMID 36959664›Full record

ArticleTrials2023

HOPPSA update: changes in the study protocol of Hysterectomy and OPPortunistic SAlpingectomy, a registry-based randomized controlled trial.

Annika Idahl, Per Liv, Anna Darelius, Elin Collins, Karin Sundfeldt, Mathias Pålsson, Annika Strandell

2 registry-linked trialsOpen access · goldFull text readClinical Trial Protocol
In one paragraph

Article in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03045965 naactive not recruitingnot on this map

Hysterectomy and Opportunistic Salpingectomy

TypeinterventionalSponsorGöteborg UniversityRan2017 to 2053Enrolled4,400ConditionsOvarian Cancer, ComplicationArmsSalpingectomy
NCT07423143 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Menopausal Impact of Opportunistic Salpingectomy for Ovarian Cancer Prevention

TypeinterventionalSponsorUmeå UniversityRan2026 to 2057Enrolled2,100ConditionsMenopause, Opportunistic SalpingectomyArmsOpportunistic salpingectomy
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Annika IdahlDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden. annika.idahl@umu.se.ORCID http://orcid.org/0000-0002-7865-4560
Per LivDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Anna DareliusDepartment of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Elin CollinsDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
Karin SundfeldtDepartment of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Mathias PålssonDepartment of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Annika StrandellDepartment of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
University of Gothenburg · SEUmeå University · SE

Funding

The Wingless Transduction Pathway in Synapse DevelopmentR37MH070000 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BUDNIK, VIVIAN G. · 2014 to 2023
$4.2M
The Wingless Transduction Pathway in Synapse DevelopmentR01MH070000 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BUDNIK, VIVIAN G. · 2004 to 2013
$3.6M
Cancerfonden CAN 2017/464Cancerfonden CAN 21 1408 PjCancer Research Foundation in Northern Sweden AMP 17-859Cancer Research Foundation in Northern Sweden LP 17-2169Cancer Research Foundation in Northern Sweden LP 22-2314Governmental funding after regional HTA 2017-01832Governmental funding after regional HTA HTA ALF 2016-86Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland VGFOUREG-650491Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland VGFOUREG-940745Jane och Dan Olssons Stiftelse 2016-49Regionala Forskningsrådet Uppsala/Örebro RFR 652-621Swedish governmental grants to researchers in the public health service ALFGBG- 720291Swedish governmental grants to researchers in the public health service ALFGBG-965130Swedish governmental grants to researchers in the public health service ALFRV-7000003Swedish governmental grants to researchers in the public health service ALFVLL-7000001Swedish governmental grants to researchers in the public health service ALF VLL-7000003
6 · The paper itself

Abstract

backgroundThe HOPPSA trial is a multi-center national registry-based randomized controlled trial to test the safety and effectiveness of performing opportunistic salpingectomy at hysterectomy to reduce the risk of epithelial ovarian cancer (EOC). The study protocol was first published in January 2019 and is available at https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-3083-8 . Here, we report amendments made to the study protocol since commencement of the trial. CHANGES IN METHODS AND ANALYSIS: The primary outcomes analyses have been changed. (1) Complications will be analyzed using binomial generalized estimating equation (GEE) with log link function, while the unadjusted analyses according to Miettinen and Nurminen will be performed as a sensitivity analysis. (2) Absolute change in Menopause Rating Scale (MRS) will primarily be analyzed using a mixed effects model, adjusted for baseline MRS and center as a random effect. (3) Time to EOC will be analyzed using the mixed effects Cox regression model with center as random effect, while the unadjusted log-rank test will be performed as a sensitivity analysis. The primary outcome Complications will be based solely on the specific assessment in the GynOp quality registry. The Clavien-Dindo classification will be evaluated as a secondary outcome. Furthermore, MRS is also measured three years postoperatively to better pinpoint the onset of menopausal symptoms. DISCUSSION: The changes to the protocol mainly concern the analyses of data. No changes to recruitment, randomization, intervention, or follow-up of primary outcomes have been made. An interim analysis during 2021 concluded that the study should continue until the target sample size is reached.

trial registrationClinicalTrials.gov, NCT03045965 . Registered 8 February 2017.

Indexed as

HysterectomyOvarian NeoplasmsCarcinoma, Ovarian EpithelialFemaleHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicRegistriesSalpingectomyTreatment OutcomeComplicationsHOPPSAHysterectomyMenopausal symptomsOpportunistic salpingectomyOvarian cancer

Identifiers

PMID36959664
PMCPMC10037841
OpenAlexW4360805169

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read4
identifiers read1
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.